Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuck ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, Wright S, McConlogue L. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet. 2001 Jun 1;10(12):1317-24. PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. A major conclusion of this paper is not proven by the data presented. That conclusion is that BACE1 is the primary β-secretase of the brain. That conclusion was arrived at based on β-secretase activity in cultured brain cells and brain homogenates. However, each of those assays contained E64, a potent, cathepsin inhibitor. The results, thus, do not rule out cathepsins as having β-secretase activity.

    View all comments by Greg Hook

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. BACE RNAi Scores in Mouse Model of AD
  2. Prague: Aβ Rehabilitated as an Antimicrobial Protein?
  3. Target BACE: Better Than Ever?
  4. What Exactly Does BACE Do in Adults?

Webinars

  1. RNAi in Neurodegenerative Diseases—What's the Therapeutic Potential?
  2. Novel Substrates for BACE1 Beg the Question: What's the Biological Function of β-Secretase?

Research Timeline Event

  1. BACE1 knockout mice are viable